510(k) Report

510(k) · Cleared

Recalled · 2011

Haemonetics Cardiovascular Perioperative Autotransfusion System (Cardiopat)

K053000510(k) SpecialCleared Nov 21, 200527-day reviewClass II21 CFR 868.5830Recalls 3

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Haemonetics Corp. · CAC Apparatus, Autotransfusion

Cleared on Nov 21, 2005 as substantially equivalent to K043127 (Haemonetics Corp., 2005) after a 27-day review. Its family tree reaches back 1 generation to 2005. It has been recalled 3 times.

Decided
Nov 21, 2005
Review
27 days
Class
Class II
Product code
CAC
Recalls
3
Predicates
1

Its longest line of descent runs back 1 generation to K043127 (2005). No later device cites it as a predicate yet.

K043127 · Haemonetics Cardiovascular Perioperative Autotransfusion System · Haemonetics Corp. · 2005 · recalled2006
  1. Root · 1 generation backK043127 Haemonetics Cardiovascular Perioperative Autotransfusion SystemHaemonetics Corp. · 2005 · Recalled
  2. This deviceK053000 Haemonetics Cardiovascular Perioperative Autotransfusion System…Haemonetics Corp. · 2005
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−1K043127Haemonetics Cardiovascular Perioperative Autotransfusion SystemHaemonetics Corp.20051
0 (this device)K053000Haemonetics Cardiovascular Perioperative Autotransfusion System (Cardiopat)Haemonetics Corp.2005—
FIG. 1 — Lineage of K053000, 2005–2005Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in CAC? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new CAC device

  1. #1 K240426 Aventus Clot Management Systemscore 11.2 · 4 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K043127Haemonetics Cardiovascular Perioperative Autotransfusion SystemHaemonetics Corp.20051

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

Recalls of this device

DateClassRecallRoot causeReason
Jul 27, 2011Not classifiedZ-2956-2011Component design/selectionUpdated Operations Manual for the deployment of the spill collection system and cleaning
Jan 25, 2011Not classifiedZ-1391-2011Labeling designUpdate Instructions for Use for the CardioPAT® Manual for Leak Detection. User may mis-interpret the air-leak rate displayed by the cardioPAT device when making a determination about chest-drain removal, which could result in the patient…
Oct 15, 2007Not classifiedZ-0358-2008Labeling designLabeling (additional) use instructions: to clarify proper position of cardioPAT device and post-op line to prevent fluid build up from patient's chest

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • Its one ancestor has a recall.

How does its category compare?

All CAC devices

CAC Apparatus, Autotransfusion: FDA decisions, review times, recalls and adverse event reports over 20 years.

FDA decisions per year · CAC

3in 2024

2008: 12010: 42011: 22012: 32013: 12014: 32016: 22017: 12018: 22019: 12020: 12021: 42022: 12023: 22024: 3
2007high 4 (2010) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · CAC

91in 2024

2010: 123 days median2012: 90 days median2014: 269 days median2021: 155 days median2024: 91 days median
2007high 269 (2014) · low 90 (2012)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · CAC

7in 2023

2007: 12008: 52009: 252010: 32011: 32013: 92017: 22018: 22019: 232023: 7, 2 Class I
2007high 25 (2009) · low 0 (2012)2026

Class I (2 since 2007) Class II/III not classified

Adverse event reports per year · CAC

128in 2025

2007: 352008: 122009: 682010: 1152011: 9392012: 2492013: 1532014: 902015: 872016: 732017: 882018: 872019: 642020: 1082021: 732022: 652023: 392024: 1292025: 128
2007high 939 (2011) · low 12 (2008)2025

MAUDE reports naming product code CAC, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—135
20081—512
20090—2568
201041233115
20112—3939
20123900249
20131—9153
20143269090
20150—087
20162—073
20171—288
20182—287
20191—2364
20201—0108
20214155073
20221—065
20232—7 (2)39
20243910129
20250—0128
20260—0—

What is it indicated for?

The Haemonetics® Cardiovascular Perioperative Autotransfusion System (cardioPATTM) is indicated for use to salvage red blood cells from blood lost intraoperatively and postoperatively during cardiovascular surgical procedures, where the expected rate of processing of salvaged blood and fluid aspirated from the surgical site is less than or equal to two liters per hour. Autotransfusion is indicated for patients who meet at least one of the following…

Read the full statement (161 words)

The Haemonetics® Cardiovascular Perioperative Autotransfusion System (cardioPATTM) is indicated for use to salvage red blood cells from blood lost intraoperatively and postoperatively during cardiovascular surgical procedures, where the expected rate of processing of salvaged blood and fluid aspirated from the surgical site is less than or equal to two liters per hour.

Autotransfusion is indicated for patients who meet at least one of the following criteria:

* The patient is expected to lose sufficient blood in the perioperative period, so as to require red blood cell transfusion, and autotransfusion will likely reduce or eliminate the need for allogeneic blood transfusion.

* Religious beliefs cause the patient to refuse allogeneic transfusion, but accept autologous transfusion.

* Compatible allogeneic blood is not available.

* The patient is unable to donate sufficient quantities of autologous blood prior to surgery to adequately cover the anticipated transfusion requirement.

* The patient or physician prefers perioperative autotransfusion rather than preoperative autologous donation or transfusion of allogeneic blood.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K053000: Haemonetics Cardiovascular Perioperative Autotransfusion System (Cardiopat).” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 3, 2026. https://510kreport.com/device/K053000

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026